Cardiovascular mechanisms of thyroid hormones and heart failure: Current knowledge and perspectives

• Published in: World journal of cardiology Vol. 16; no. 5; pp. 226 - 230
• Main Author: Čulić, Viktor
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 26.05.2024
• Subjects: Heart failure; Non-thyroidal illness syndrome; Low triiodothyronine syndrome; Therapy; Triiodothyronine; Thyroxine
• ISSN: 1949-8462; 1949-8462
• DOI: 10.4330/wjc.v16.i5.226

A multiple hormonal imbalance that accompanies heart failure (HF) may have a significant impact on the clinical course in such patients. The non-thyroidal illness syndrome (NTIS), also referred to as euthyroid sick syndrome or low triiodothyronine syndrome, can be found in about 30% of patients with HF. NTIS represents a systemic adaptation to chronic illness that is associated with increased cardiac and overall mortality in patients with HF. While conclusions on thyroid-stimulating hormone, free triiodothyronine, total and free thyroxine are currently unresolved, serum total triiodothyronine levels and the ratio of free triiodothyronine to free thyroxine seem to provide the best correlates to the echocardiographic, laboratory and clinical parameters of disease severity. HF patients with either hyper- or hypothyroidism should be treated according to the appropriate guidelines, but the therapeutic approach to NTIS, with or without HF, is still a matter of debate. Possible treatment options include better individual titration of levothyroxine therapy, combined triiodothyronine plus thyroxine therapy and natural measures to increase triiodothyronine. Future research should further examine the cellular and tissue mechanisms of NTIS as well as new therapeutic avenues in patients with HF.